Breaking News

InVivo Therapeutics Names Investor Relations VP

July 1, 2014

McNulty to head strategic focus for spinal cord injury efforts

Christopher McNulty has been appointed to an expanded role as vice president of investor relations and corporate communications at InVivo Therapeutics, in addition to his position as vice president of business development. Mr. McNulty will lead an integrated corporate communications effort for its strategic focus on developing therapies for spinal cord injury that will include investor relations, public relations, medical/scientific communications, patient advocacy, and the spinal cord injury (SCI) community. 
 
Mr. McNulty joins the company from Repligen Corp., where he served as senior director of business development, responsible for out-licensing programs for rare neurodegenerative diseases. Previously, he was director of corporate development at Seventh Sense Biosystems and associate director of business development and alliance management at Genzyme Corp.
 
Mark Perrin, InVivo’s chief executive officer, said, “Combining our investor relations, public relations, medical communications, and patient advocacy efforts into a comprehensive and synergistic corporate communications function will improve our communication efforts to all our constituents. We have engaged excellent partners with expertise in each of these areas to assist us in our efforts, and I look forward to our future activities."
blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision